pharma · Minimal Residual Disease · Pancreatic Ductal Adenocarcinoma · ELTX
Elicio Therapeutics
Elicio Therapeutics is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker ELTX. Primary therapeutic focus areas include Minimal Residual Disease, Pancreatic Ductal Adenocarcinoma. NovaPhar
Boston, USA HQ
47 Employees
Public company Type
ELTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boston, USA
- Employees
- 47
- Programs
- 2
- Drugs
- 0
- Patents
- 4
ELI-002 2P
Phase 1 · small molecule · Minimal Residual Disease
ELI-002 2P for Minimal Residual Disease is a Phase 1 program (small_molecule) at Elicio Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code ELI-002-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Elicio Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Minimal Residual Disease
- Status
- completed
- Trials
- 1